Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

Date publication

septembre 2018

Journal

Journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29869016

Résumé

Selective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness.

Mots clés

Crohn’s disease, Inflammatory bowel disease, Real-world effectiveness, Ulcerative colitis, Vedolizumab

Référence

J. Gastroenterol.. 2018 Sep;53(9):1048-1064